Cyclerion Therapeutics (CYCN) Announces CY6463 Pipeline Progress; Reports Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall St futures edge up as Hormuz progress weighs down oil prices
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
August 9, 2022 4:00 PM EDTPositive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS)
Study in Alzheimers Disease with vascular pathology (ADv) enrollment ongoing
Appointed Steven E. Hyman, M.D. to its Board of Directors
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced second quarter 2022... More
